Across TCGA pan-cancer cohorts, SAPCD2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SAPCD2 data layer compared with 29 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SAPCD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SAPCD2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LSCC and GBM are the cancer types where SAPCD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	0.601	1.000	.027	8	view →
GBM	OS	Quartile	All	1.000	0.615	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SAPCD2 tumor-vs-normal RNA expression · all SAPCD2 data types